A Multicenter Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Brief description of study

The purpose of this study is to: o Test the safety of the study drugs, lenvatinib and pembrolizumab when given together o See how well they work to control or stop your cancer o See how well your body handles the study drugs o Find out how lenvatinib is absorbed and broken down in your body when given with pembrolizumab o See if the study drugs help patients live longer Pembrolizumab (MK-3475), also known as KEYTRUDA®, and lenvatinib (MK-7902/E7080) also known as Lenvima®, have been approved by certain health authorities for the treatment of various cancers. However, they may not be approved for your exact type of cancer in your country.


Clinical Study Identifier: s18-01189
ClinicalTrials.gov Identifier: NCT03797326
Principal Investigator: Deirdre J Cohen
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.